Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-20. (Canceled)

21. (New) An siRNA molecule comprising a sense strand hybridized to an antisense strand, wherein the antisense strand targets a region in a 17AA site of a Wilms' tumor gene transcript, and wherein the siRNA suppresses cell growth.

22. (New) The siRNA molecule of claim 21, wherein each of the sense and antisense strands is 15 to 49 bases in length.

23. (New) The siRNA molecule of claim 21, wherein the siRNA molecule has a single stranded hairpin loop linking the sense and antisense strands.

24. (New) The siRNA molecule of claim 21, wherein at least one of the sense and antisense strands has a single-stranded overhang at one end.

25. (New) The siRNA molecule of claim 1, wherein the sense strand comprises SEQ ID NO:1 and the antisense strand comprises SEQ ID NO:2.

26. (New) The siRNA molecule of claim 1, wherein the sense strand comprises the RNA equivalent of the DNA sequence of SEQ ID NO:11.

27. (New) A DNA comprising a sequence that is transcribed into a sense RNA strand and an antisense RNA strand that hybridize together to form an siRNA that suppresses cell

growth, wherein the antisense RNA strand targets a region in a 17AA site of a Wilms' tumor gene transcript.

28. (New) The DNA of claim 27, wherein the sense and antisense RNA strands are in a single transcript and are linked by an RNA linker that forms a single stranded hairpin loop when the sense and antisense RNA strands hybridize.

29. (New) The DNA of claim 27, wherein the sense and antisense RNA strands are transcribed from the DNA in separate transcripts.

30. (New) The DNA of claim 27, wherein each of the sense and antisense RNA strands is 15 to 49 bases in length.

31. (New) The DNA of claim 27, wherein at least one of the sense and antisense RNA strands has a single-stranded overhang at one end.

32. (New) The DNA of claim 27, wherein the sense RNA strand comprises SEQ ID NO:1.

33. (New) The DNA of claim 27, wherein the sense RNA strand comprises the RNA equivalent of the DNA sequence of SEQ ID NO:11.

34. (New) A pair of DNAs, the first DNA comprising a sequence that is transcribed into a sense RNA strand and the second DNA comprising a sequence that is transcribed into an antisense RNA strand, wherein the sense and antisense RNA strands hybridize together to form an siRNA that suppresses cell growth, and wherein the antisense RNA strand targets a region in a 17AA site of a Wilms' tumor gene transcript.

35. (New) The pair of DNAs of claim 34, wherein each of the sense and antisense RNA strands is 15 to 49 bases in length.

36. (New) The pair of DNAs of claim 34, wherein at least one of the sense and antisense RNA strands has a single-stranded overhang at one end.

37. (New) The pair of DNAs of claim 34, wherein the sense RNA strand comprises SEQ ID NO:1.

38. (New) The pair of DNAs of claim 34, wherein the sense RNA strand comprises the RNA equivalent of the DNA sequence of SEQ ID NO:11.

39. (New) A vector comprising the DNA of claim 27.

40. (New) A vector comprising the DNA of claim 28.

41. (New) A vector comprising the DNA of claim 29.

42. (New) A vector comprising the DNA of claim 30.

43. (New) A vector comprising the DNA of claim 31.

44. (New) A vector comprising the DNA of claim 32.

45. (New) A vector comprising the DNA of claim 33.

46. (New) A pair of vectors, each vector comprising one of the DNAs of claim 34.

47. (New) The siRNA molecule of claim 21, wherein the siRNA inhibits growth of a cancer cell.

48. (New) The siRNA molecule of claim 21, wherein the siRNA induces death of a cancer cell.

49. (New) The siRNA molecule of claim 21, wherein the siRNA inhibits growth of a fibrosarcoma cell, colon cancer cell, leukemia cell, or gastric cancer cell.

50. (New) The siRNA molecule of claim 21, wherein the siRNA enhances sensitivity of a cancer cell to an anticancer agent.

51. (New) The siRNA molecule of claim 21, wherein the siRNA enhances sensitivity of a cancer cell to a cell-death-inducing agent.

52. (New) The siRNA molecule of claim 21, wherein the siRNA enhances cytochrome c release into cytoplasm of a cell.